No abstract

No abstract

No abstract

The pathogenesis of bromoderma is still under debate. Some authors have proposed that halogenodermas belong to the group of hypersensitivity reactions. 1,3,5 However, accumulation of the halogenide seems to play a pivotal role leading to a rather toxic inflammatory reaction provoked by the elimination of bromine through the eccrine and sebaceous glands. 1,3,5 Indeed, bromides show slow elimination rates and both bromoderma and bromism may persist for weeks after drug withdrawal. 9 Diagnosis of bromoderma is primarily based on the clinical features and history of bromine intake. 1,2,5 Histology is rather unspecific but helpful in excluding other differential diagnoses. However, pseudo-hyperchloraemia is a typical laboratory finding, which is due to the method used for serum chloride assessment. Since the electric charge of chloride and bromide is the same, enhanced serum bromide is detected by an increase in chloride. 5 Treatment mainly relies on the withdrawal of the offending drug. 2,4,6 In addition, diuretics, such as furosemide and ethacrynic acid, could be administered because of their activity in accelerating bromide excretion through the kidneys. 9,10 Local therapies include topical corticosteroids and antiseptic measurements. 2,4,6 Our case highlights that bromoderma has still to be considered as a side effect of therapeutic interventions utilizing bromide-containing agents. Funding sources: None.

I), which are slightly lower than the present results. Interestingly, the reported rate of adverse effects in these studies (10%-41%) was similar to the present rate (33%); in general, the adverse effects were mild and transient. The present study is limited by the absence of a control group.In conclusion, treatment with PCT-OD at a dosage of 0.1 mg/kg/day biweekly is a potential therapeutic option for adults with AT/AU.

Folliculitis decalvans (FD) is a primary neutrophilic scarring alopecia characterized by perifollicular papules, crusts, and pustules frequently located on the vertex. FD may affect young men and women. Since it may lead to hair loss, it can have a negative impact on patients' quality of life. Nevertheless, studies have focused on clinical, prognostic, and therapeutic aspects without considering the psychological impact of FD. In our study, we found that FD patients experienced a considerable impact on their quality of life. Interestingly, almost half of the patients considered that their alopecia was related to a poor medical care in their past. To our knowledge, this is the first description of the impact of FD on patients' quality of life, and it highlights the importance of psychological support for these patients.

No abstract

No abstract